NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
Clinical Trials
13 trialsNCT01779206 2025-04-08
ADAPT
West German Study Group
Phase 2/3 Completed
NCT02923258 2024-06-20
Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2/3 Completed
NCT03607656 2023-12-18
CHANGE
Shanghai University of Traditional Chinese Medicine
Phase 2/3 Completed
NCT02766335 2023-05-25
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network
Phase 2/3 Completed
NCT02661971 2022-07-11
RAMSES/FLOT7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Completed
NCT01905657 2021-10-06
MK-3475-010
Merck Sharp & Dohme LLC
Phase 2/3 Completed
NCT02965378 2021-05-27
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Phase 2/3 Completed
NCT01216644 2019-06-19
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest
Phase 2/3 Completed
NCT02959749 2018-02-14
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase 2/3 Completed
NCT01829178 2015-05-13
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Tehran University of Medical Sciences
Phase 2/3 Completed
NCT00261703 2012-05-11
Docetaxel in Head and Neck Cancer
Sanofi
Phase 2/3 Completed
NCT00401323 2011-01-20
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Phase 2/3 Completed